Article
Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.
Current drug metabolism - 1 Sept 2009
Wang B, Wang J, Huang S-Q, Su H-H, Zhou S-F
Abstract excerpt
Human cytochrome P450 2C9 (CYP2C9) accounts for approximately 20% of total hepatic CYP content and metabolizes approximately 15% clinically used drugs including S-warfarin, tolbutamide, phenytoin, losartan, diclofenac, and celecoxib. To date, there are at least 33 variants of CYP2C9 (*1B through to *34) being identified. CYP2C9*2 and CYP2C9*3 differ from the wild-type CYP2C9*1 by a single point mutation: CYP2C9*2...
Topics
- Animals
- Aryl Hydrocarbon Hydroxylases
- Clinical Trials as Topic
- Cytochrome P-450 CYP2C9
- Drug-Related Side Effects and Adverse Reactions
- Genetic Variation
- Humans
- Liver
- Pharmaceutical Preparations
- Pharmacogenetics